{"id":"barnidipine","rwe":[{"pmid":"39913972","year":"2025","title":"UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"39760129","year":"2025","title":"Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort.","finding":"","journal":"International journal of cardiology. Cardiovascular risk and prevention","studyType":"Clinical Study"},{"pmid":"39652122","year":"2025","title":"Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study.","finding":"","journal":"Clinical rheumatology","studyType":"Clinical Study"},{"pmid":"34528268","year":"2022","title":"Exploring an experimental combination of analytical quality by design and green analytical chemistry approaches for development of HPTLC densitometric protocol for the analysis of barnidipine hydrochloride.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"},{"pmid":"34137272","year":"2021","title":"Computational drug repositioning for ischemic stroke: neuroprotective drug discovery.","finding":"","journal":"Future medicinal chemistry","studyType":"Clinical Study"}],"tags":[{"label":"barnidipine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-gated L-type calcium channel","category":"target"},{"label":"CACNA1C","category":"gene"},{"label":"CACNA1D","category":"gene"},{"label":"C08CA12","category":"atc"},{"label":"Active","category":"status"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":70.986,"date":"","count":41,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=71)"},{"llr":49.372,"date":"","count":14,"signal":"Hypertensive crisis","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=49)"}],"commonSideEffects":[{"effect":"Drug interaction","drugRate":"LLR 71","severity":"common"},{"effect":"Hypertensive crisis","drugRate":"LLR 49","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vasexten","offLabel":[],"synonyms":["barnidipine","mepirodipine","vasexten","mepirodipine hydrobromide","mepirodipine hydrochloride"],"timeline":[],"aiSummary":"Vasexten, also known as BARNIDIPINE, is a small molecule drug that targets voltage-gated L-type calcium channels. It is classified as a barnidipine drug class and is used to treat certain cardiovascular conditions. The commercial status of Vasexten is unclear, as it is not FDA-approved and its patent status is unknown. Key safety considerations include its low bioavailability of 1%. Vasexten is developed by an unknown original developer and is currently owned by an unknown entity.","brandName":"Vasexten","ecosystem":[],"mechanism":{"target":"Voltage-gated L-type calcium channel","targets":[{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"},{"gene":"CACNA1D","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1D"}],"modality":"Small Molecule","drugClass":"barnidipine","explanation":"Imagine your blood vessels are like roads in your body. When you have high blood pressure, the roads get congested and narrow. Vasexten helps to relax the muscles around the roads, making them wider and allowing blood to flow more easily. This helps to lower blood pressure and reduce the risk of heart disease.","oneSentence":"Vasexten works by blocking calcium channels in the heart and blood vessels, which helps to relax and widen blood vessels, reducing blood pressure.","technicalDetail":"Vasexten acts as a selective L-type calcium channel blocker, inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/290","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BARNIDIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BARNIDIPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:49:32.049424","biosimilars":[],"competitors":[{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"felodipine","drugSlug":"felodipine","fdaApproval":"1991-07-25","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isradipine","drugSlug":"isradipine","fdaApproval":"1990-12-20","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nicardipine","drugSlug":"nicardipine","fdaApproval":"1988-12-21","patentExpiry":"Dec 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nifedipine","drugSlug":"nifedipine","fdaApproval":"1981-12-31","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nimodipine","drugSlug":"nimodipine","fdaApproval":"1988-12-28","patentExpiry":"Apr 16, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nisoldipine","drugSlug":"nisoldipine","fdaApproval":"1995-02-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clevidipine","drugSlug":"clevidipine","fdaApproval":"2008-08-01","patentExpiry":"Oct 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"barnidipine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-class"},{"drugId":"felodipine","brandName":"felodipine","genericName":"felodipine","approvalYear":"1991","relationship":"same-class"},{"drugId":"isradipine","brandName":"isradipine","genericName":"isradipine","approvalYear":"1990","relationship":"same-class"},{"drugId":"nicardipine","brandName":"nicardipine","genericName":"nicardipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nifedipine","brandName":"nifedipine","genericName":"nifedipine","approvalYear":"1981","relationship":"same-class"},{"drugId":"nimodipine","brandName":"nimodipine","genericName":"nimodipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nisoldipine","brandName":"nisoldipine","genericName":"nisoldipine","approvalYear":"1995","relationship":"same-class"},{"drugId":"clevidipine","brandName":"clevidipine","genericName":"clevidipine","approvalYear":"2008","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT00728858","phase":"","title":"The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-04","conditions":["Hypertension"],"enrollment":43,"completionDate":"2007-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"009143","UNII":"2VBY96ASWJ","CHEBI":"CHEBI:135793","INN_ID":"6746","RXNORM":"39879","UMLSCUI":"C0078703","ChEMBL_ID":"CHEMBL2103761","KEGG_DRUG":"D07494","DRUGBANK_ID":"DB09227","PUBCHEM_CID":"443869","SNOMEDCT_US":"698052006","MESH_SUPPLEMENTAL_RECORD_UI":"C050699"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"1%"},"publicationCount":94,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C08CA12","allCodes":["C08CA12"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Mar","pmid":"39913972","title":"UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025 Mar","pmid":"39760129","title":"Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort.","journal":"International journal of cardiology. Cardiovascular risk and prevention"},{"date":"2025 Jan","pmid":"39652122","title":"Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study.","journal":"Clinical rheumatology"},{"date":"2022 Jan","pmid":"34528268","title":"Exploring an experimental combination of analytical quality by design and green analytical chemistry approaches for development of HPTLC densitometric protocol for the analysis of barnidipine hydrochloride.","journal":"Biomedical chromatography : BMC"},{"date":"2021 Aug","pmid":"34137272","title":"Computational drug repositioning for ischemic stroke: neuroprotective drug discovery.","journal":"Future medicinal chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}